Business Context and Reporting Period
This Form 8-K Current Report was filed by Bone Biologics Corp (BBLG) on December 14, 2023, with the earliest event reported on the same date. The Company, incorporated in Delaware, is a developing biotechnology firm focused on bone biologics. The report primarily addresses a material modification to the rights of security holders regarding a reverse stock split.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document is a corporate action report rather than a financial results statement.
Material Changes
- Reverse Stock Split: The Company filed a Certificate of Amendment to effect a 1-for-8 reverse stock split of its Common Stock.
- Effective Date: The split is effective as of 12:01 a.m. Eastern Time on December 20, 2023.
- Trading Details: Common Stock will trade under the existing symbol "BBLG" on the Nasdaq Capital Market post-split. Warrants will continue to trade under "BBLGW."
- Share Mechanics: Every 8 shares of Common Stock will be combined into one share. Fractional shares will be rounded up to the nearest whole share.
- Adjustments: Proportionate adjustments will be made to warrant exercise prices, shares issuable upon warrant exercise, and equity plan awards. The par value ($0.001) and voting rights remain unchanged.
Guidance, Outlook, and Risks
The filing includes forward-looking statements regarding the timing and implementation of the reverse stock split. Management notes that actual results may differ due to risks associated with being an undercapitalized developing company. Specific risks are referenced in the Company's Annual Report on Form 10-K for the year ended December 31, 2022. The Company undertakes no obligation to update these statements.
Investor Verification Checklist
- Verify the new CUSIP identifier for Common Stock (098070501) for trading purposes.
- Confirm the treatment of fractional shares (rounded up) in personal brokerage accounts.
- Review the adjusted exercise price and share count for any outstanding warrants (BBLGW).
- Check the Company's Form 10-K for the year ended December 31, 2022, for detailed risk factors and financial condition.